AN2 Therapeutics Inc 뉴스 - ANTX | 주식 나스닥 | ADVFN

다우존스 지수

실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
AN2 Therapeutics Inc (ANTX)
AN2 Therapeutics Inc (ANTX) 뉴스

AN2 Therapeutics Inc (ANTX)

1.15

0.00

(0.00%)

마감 20 2월 6:00AM

0.00

0.00

(0.00%)

시간외 거래: -

개인 투자자를 위한 전문가급 도구.

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

AN2 Therapeutics to Participate at Upcoming Investor Conferences

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics...

glenn1919

glenn1919 2 월 전

ANTX.....................https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 2 월 전

ANTX........................https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783

TrendTrade2016

TrendTrade2016 3 월 전

ANTX NEXT WEEK WATCH

stocksrising

stocksrising 3 월 전

Open market purchase always welcomed :)..even if tiny 😜

Common Stock-CEO
11/18/2024
50,000
A
$0.9994
1,065,76

TrendTrade2016

TrendTrade2016 3 월 전

ANTX MINI BIO BEAST

stocksrising

stocksrising 3 월 전

I haven’t done much DD on this bio, but it seems they have several readouts within 6-12mos. that could propel stock higher (especially with the $$$ runway position)… as you know, any biotech is risky but I like the odds on this one and starter position is small for now…I did copy this from release that I found appealing:

Boron Chemistry Pipeline

Additional development programs are underway and focused on targets in infectious diseases and oncology with high unmet needs. The Company anticipates delivering up to three development compounds in 2025.

Global Health

In October, the Company announced that it received a second-year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel boron containing small molecules for the treatment of tuberculosis and malaria. The Company will continue its efforts to tackle global health disease through non-dilutive funding.

eyeownu

eyeownu 3 월 전

NOPE. took my looses moved them over to $EBS and made it all back. do you notice anything promising that warrants investing in this company besides the cash on hand?

stocksrising

stocksrising 3 월 전

Picked up a bit more down here at $1ish, you still in??

Monksdream

Monksdream 6 월 전

ANTX new 52 week low

Monksdream

Monksdream 7 월 전

eyeownu

eyeownu 7 월 전

glenn1919

glenn1919 8 월 전

ANTX..............https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783

GO4AWILDRIDE

GO4AWILDRIDE 11 월 전

FROM 3/28 NEWS:

Cash, cash equivalents, and investments of $134.5 million at December 31, 2023

GO4AWILDRIDE

GO4AWILDRIDE

GO4AWILDRIDE 11 월 전

THE FOLLOWING FROM THE 3/28 NEWS:

“AN2’s cash position remains strong as we advance our innovative boron-based pipeline. Following the recent meeting of the independent Data Safety Monitoring Board, we continue to believe in the potential of epetraborole to become an important component of the backbone therapy for NTM lung disease,” said Eric Easom, Co-Founder, President and Chief Executive Officer. “Patients enrolled in the epetraborole Phase 2/3 trial in treatment refractory lung disease caused by MAC continue to be dosed while new enrollment in the Phase 3 part of the trial remains paused. Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer. Analysis of the baseline patient demographics from the trial show a highly complex and refractory patient population, which we plan to discuss with the FDA in the coming months.”

GO4AWILDRIDE

GO4AWILDRIDE

GO4AWILDRIDE 11 월 전

Monksdream

Did you read the 3/28 news from the compay?

Seems like the market is looking to chase the price up.

GLTU

GO4AWILDRIDE

GO4AWILDRIDE

GO4AWILDRIDE 11 월 전

Monksdream

Seems like a nice rebound is starting to occur.

GLTU

GO4AWILDRIDE

Monksdream

Monksdream 12 월 전

ANTX new 52 week low

Monksdream

Monksdream 12 월 전

ANTX new 52 week low

Monksdream

Monksdream 1 년 전

ANTX new 52 week low

AN2 Therapeutics

Mammoth Resources (PK)

Marquee Raine Acquisition

ESG Global Impact Capital

Bnp Paribas Issuance

Invesco European Oil & G...

Angelica Pna PNA

Vontobel Financial Produ...

Vontobel Financial Produ...

Xtrackers Msci Emu Esg U...

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관